AGIO

Several events have impacted AGIO's stock price in the past six months. The FDA approved AQVESME in December 2025. Topline results from the Phase 3 RISE UP trial in Sickle Cell Disease were announced in November 2025. Agios reported Q4 and full-year 2025 financial results on February 12, 2026, including AQVESME FDA approval and PYRUKYND Q4 net revenue of $20.0M. Agios advanced mitapivat toward potential U.S. accelerated approval in sickle cell disease following a pre-sNDA meeting with the FDA on March 31, 2026. Agios reported Q1 2026 financial results on April 29, 2026, showing strong early demand for AQVESME in the U.S. with $18.8M in U.S. net revenue, leading to a 13.10% stock gain. Analyst sentiment has been mixed but cautious, with a "Hold" consensus and a target price of $41.56.